ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

$1.88  -0.04 (-2.08%)
As of 09/26/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  11/15/2010
Outstanding shares:  149,950,606
Average volume:  712,329
Market cap:   $287,905,164
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BZ0QMB7
Valuation   (See tab for details)
PE ratio:   -3.40
PB ratio:   1.64
PS ratio:   13.42
Return on equity:   -45.60%
Net income %:   -352.49%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy